60 Degrees Pharma to Disclose Tafenoquine Babesiosis Trial Results on October 6
On October 1, 2026, 60 Degrees Pharmaceuticals announced it will disclose interim clinical trial results for tafenoquine in hospitalized severe babesiosis patients on October 6, 2026. The company previously crossed … Read More